Beneficial Effects of Acute and Repeated Administrations of σ Receptor Agonists on Behavioral Despair in Mice Exposed to Tail Suspension
In an attempt to examine whether σ receptor agonists alleviate behavioral despair, we investigated the effects of σ receptor agonists on the tail suspension-induced immobility in mice. The acute and repeated (14 days) administrations of σ 1 receptor agonists, such as 1-(3,4-dimethoxyphenethyl)-4-(3-...
Gespeichert in:
Veröffentlicht in: | Pharmacology, biochemistry and behavior biochemistry and behavior, 1998-11, Vol.61 (3), p.247-252 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | In an attempt to examine whether σ receptor agonists alleviate behavioral despair, we investigated the effects of σ receptor agonists on the tail suspension-induced immobility in mice. The acute and repeated (14 days) administrations of σ
1 receptor agonists, such as 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA4503) (1 and/or 3 mg/kg) and (+)-pentazocine (5.6 mg/kg), σ
1/2 receptor agonists, such as 1,3-di(2-tolyl)guanidine (DTG) (3 and/or 5.6 mg/kg), desipramine (7.5 and/or 15 mg/kg), and fluoxetine (10 and/or 20 mg/kg), reduced immobility in mice exposed to tail suspension.
N,N-Dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100), a σ
1 receptor antagonist, significantly antagonized the decrease in immobility induced by acute administrations of SA4503 (1 mg/kg) and (+)-pentazocine (5.6 mg/kg). Although not significant, NE-100 showed a tendency to inhibit the DTG (5.6 mg/kg)-induced decrease in immobility. In contrast, repeated administrations of SA4503 (1 and 3 mg/kg), (+)-pentazocine (5.6 mg/kg) or DTG (5.6 mg/kg) failed to affect the increase in body weight. These results suggest that acute and repeated stimulations of σ, possibly a σ
1 receptor subtype, alleviate behavioral despair, unaccompanied with changes in body weight. |
---|---|
ISSN: | 0091-3057 1873-5177 |
DOI: | 10.1016/S0091-3057(98)00093-8 |